202. Dylan Beynon, Founder & CEO of Mindbloom
Today, I’m joined by Dylan Beynon, founder & CEO of Mindbloom, a psychedelics-assisted therapy platform. After discovering the transformative potential of psychedelics, Dylan Beynon founded Mindbloom to empower individuals to improve their mental and emotional well-being through guided psychedelic experiences, meditation, and coaching. Facilitated by trained guides, the telemedicine platform employs clinician-prescribed ketamine therapy to alleviate symptoms of depression, anxiety, and PTSD. In this episode, we talk about barriers to care during a national mental health crisis. Plus, we explore navigating at-home psychedelic experiences and Mindbloom’s plans should psilocybin (aka “magic mushrooms”) become legal. In this episode, you’ll learn: • How ketamine therapy radically changed the lives of Dylan and his family • The difficulties of working in heavily regulated industries • Mindbloom’s therapy process and how they team up with mental healthcare providers Subscribe to the podcast → insider.fitt.co/podcast Subscribe to our newsletter → insider.fitt.co/subscribe Follow us on LinkedIn → linkedin.com/company/fittinsider Mindbloom’s Website: https://www.mindbloom.com/ Mindbloom’s socials: @mindbloom Dylan’s LinkedIn: https://www.linkedin.com/in/dylanbeynon/ - The Fitt Insider podcast is brought to you by Jack Taylor, our exclusive PR partner. More than just PR, they’re creative storytellers and brand builders who actually understand the health and wellness industry. Learn more and get in touch at https://fitt.co/jacktaylor Chapters: (00:00) Introduction (01:34) About Mindbloom (03:44) Ketamine therapy (07:57) The mental health crisis (12:29) Treating mental illness with SSRIs vs. ketamine therapy (19:39) Healthcare professionals utilizing ketamine therapy at their practice (22:54) Regulatory considerations and challenges (28:04) Patient testimonials are the best marketing (30:51) Future roadmap (33:58) Improving treatments for mental illnesses (37:32) Views on legalization of psychedelic drugs (41:48) Key Takeaway (43:09) Conclusion